Posts by: Ana Belo van Wijk, PhD

Ana Belo van Wijk, PhD

October 31, 2017October 31, 2017

Polyphor Gets New Funding to Develop Inhaled Antibiotic Murepavadin for Respiratory Diseases Like CF

News

Polyphor and the European Innovative Medicines Initiative (IMI) will fund up to 10 million euros (around $11.6 million U.S.) to support and advance the development of an inhaled formulation of Polyphor’s investigational ... Read more

October 19, 2017October 19, 2017

HOPE-1 Clinical Trial for SPX-101 Is Enrolling CF Patients in Canada and Europe

cystic fibrosis, News

The first patient has been enrolled and dosed in the HOPE-1 Phase 2 clinical trial evaluating Spyryx Biosciences‘ investigational drug SPX-101 as a treatment for cystic fibrosis (CF). The HOPE-1 study (NCT03229252) will ... Read more

September 29, 2017

Enrollment Underway in CF Clinical Trial for Ear Toxicity Caused by Antibiotics

News

The first study of cystic fibrosis (CF) patients who received antibiotics that caused inner ear disease or ototoxicity is enrolling participants, according to Sound Pharmaceuticals. The Phase 1b STOP Ototoxicity study ... Read more

September 20, 2017September 20, 2017

Antibiotic Iclaprim Granted FDA Orphan Drug Status for CF Lung Infections

cystic fibrosis, News

The U.S. Food and Drug Administration (FDA) granted orphan drug status to a broad spectrum antibiotic called iclaprim, developed by Motif Bio, for the treatment of one of the most common lung ... Read more